ProShare Advisors
RCUS icon

ProShare Advisors’s Arcus Biosciences RCUS Stock Holding History

ProShare Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282K Sell
13,053
-2,314
-15% -$50K ﹤0.01% 1378
2025
Q4 		$366K Buy
15,367
+2,377
+18% +$48.5K ﹤0.01% 1327
2025
Q3 		$177K Sell
12,990
-2,375
-15% -$24.7K ﹤0.01% 1723
2025
Q2 		$125K Buy
15,365
+2,319
+18% +$19.8K ﹤0.01% 1827
2025
Q1 		$102K Sell
13,046
-3,333
-20% -$38.6K ﹤0.01% 1829
2024
Q4 		$244K Buy
16,379
+5,038
+44% +$82.3K ﹤0.01% 1778
2024
Q3 		$173K Buy
+11,341
New +$179K ﹤0.01% 1766
2024
Q2 		– Sell
-10,846
Closed -$205K – 1969
2024
Q1 		$205K Buy
10,846
+746
+7% +$12.9K ﹤0.01% 1656
2023
Q4 		$193K Buy
+10,100
New +$161K ﹤0.01% 1648
2022
Q2 		– Sell
-8,410
Closed -$266K – 2055
2022
Q1 		$266K Sell
8,410
-1,365
-14% -$45.7K ﹤0.01% 1713
2021
Q4 		$396K Buy
9,775
+3,968
+68% +$154K ﹤0.01% 1615
2021
Q3 		$202K Sell
5,807
-5,947
-51% -$185K ﹤0.01% 1790
2021
Q2 		$323K Buy
11,754
+493
+4% +$14.1K ﹤0.01% 1849
2021
Q1 		$316K Buy
11,261
+1,923
+21% +$66.9K ﹤0.01% 1776
2020
Q4 		$242K Buy
+9,338
New +$226K ﹤0.01% 1748

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ProShare Advisors's RCUS Position: Q1 2026 in Review

ProShare Advisors reduced its Arcus Biosciences (RCUS) stake by 15% in Q1 2026, selling an estimated $50K and leaving 13,053 shares worth $282K. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

ProShare Advisors first reported a position in RCUS in Q4 2020 and has held it in 15 quarters since. The position peaked at $396K in Q4 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • ProShare Advisors held 13,053 shares of Arcus Biosciences worth $282K as of Q1 2026.
  • ProShare Advisors sold 2,314 Arcus Biosciences shares in Q1 2026, an estimated $50K.
  • Arcus Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1378 holding.
  • ProShare Advisors first reported a position in Arcus Biosciences in Q4 2020 and has held it in 15 quarters since.
  • ProShare Advisors's Arcus Biosciences position peaked at $396K in Q4 2021.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.